Centrally acting antiadrenergic (versus unexposed)

Study	Exclusion reasons	Rmk	Reference
Rezk - Methyldopa, 2016	other reason	EXCLUDED: Rezk 2019-Retracted article and all studies of the team are suspected 'The assessment of the work of Dr Rezk shows prima facie evidence of data fabrication.	Rezk Pregnancy Hypertens 2016; 6:291-294 10.1016/j.preghy.2016.05.002
Salama - Methyldopa (Controls unexposed, sick), 2019	other reason	EXCLUDED: Rezk 2019-Retracted article (Retraction Watch https://retractionwatch.com/) and all studies of the team are suspected 'The assessment of the work of Dr Rezk shows prima facie evidence of data fabrication.	Salama Pregnancy Hypertens 2019; 17:54-58 10.1016/j.preghy.2019.05.009
Rezk - Methyldopa (Controls unexposed, sick), 2019	other reason	EXCLUDED: Retracted article (Retraction Watch https://retractionwatch.com/). Overlapping: same dataset than those used by Salama 2019, but more outcomes were reported by Rezk 2020.	Rezk Hypertens Pregnancy 2020; 39:393-398 10.1080/10641955.2020.1791902